trending Market Intelligence /marketintelligence/en/news-insights/trending/4JENKPjQIqeV1oB-WNdSyA2 content esgSubNav
In This List

Dova Pharmaceuticals appoints president/CEO, chief commercial officer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Dova Pharmaceuticals appoints president/CEO, chief commercial officer

Dova Pharmaceuticals Inc. appointed David Zaccardelli president and CEO, and also named Jason Hoitt chief commercial officer.

Zaccardelli — who was previously acting CEO of Cempra Pharmaceuticals Inc. until the company's merger with Melinta Therapeutics Inc. — is replacing Alex Sapir in the president and CEO roles.

Hoitt was previously vice president and head of U.S. sales at Insmed Inc. and head of U.S. sales and senior director of medical affairs at Sarepta Therapeutics Inc.

Dova expects the appointments of Zaccardelli and Hoitt to accelerate the launch of the company's bleeding disorder drug Doptelet. The therapy was approved by the U.S. Food and Drug Administration in May to treat thrombocytopenia, a condition characterized by an abnormally low platelet count, in adults with chronic liver disease.

Dova is also seeking the U.S. FDA's approval for Doptelet as a therapy for immune thrombocytopenia, a bleeding disorder that can lead to excessive bruising and bleeding due to low levels of platelets in the blood.